Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Phosphorylated p70S6K in noninvasive low-grade urothelial carcinoma of the bladder: correlation with tumor recurrence.

Kim SJ, Kim JH, Jung HS, Lee TJ, Lee KM, Chang IH.

Asian J Androl. 2014 Jul-Aug;16(4):611-7. doi: 10.4103/1008-682X.123675. Erratum in: Asian J Androl. 2014 Jul-Aug;16(4):656.

2.

P70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression in orthotopic mouse non-muscle invasive bladder tumor model.

Chi BH, Kim SJ, Seo HK, Seo HH, Lee SJ, Kwon JK, Lee TJ, Chang IH.

J Korean Med Sci. 2015 Mar;30(3):308-16. doi: 10.3346/jkms.2015.30.3.308. Epub 2015 Feb 16.

3.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

4.

The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.

Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA.

BJU Int. 2011 Jul;108(2 Pt 2):E84-90. doi: 10.1111/j.1464-410X.2010.09844.x. Epub 2010 Nov 2.

5.

Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.

Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, De Marzo A, Steinle RE, Hsi ED, Theodorescu D, Ching CB, Eng C.

Am J Pathol. 2010 Jun;176(6):3062-72. doi: 10.2353/ajpath.2010.090872. Epub 2010 Apr 15.

6.

S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.

Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, Gschwend JE, Retz M.

PLoS One. 2011;6(11):e27509. doi: 10.1371/journal.pone.0027509. Epub 2011 Nov 15.

7.

Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.

Kyou Kwon J, Kim SJ, Hoon Kim J, Mee Lee K, Ho Chang I.

Urol Oncol. 2014 Jan;32(1):51.e27-35. doi: 10.1016/j.urolonc.2013.08.005. Epub 2013 Nov 13.

PMID:
24239466
8.

Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma.

Li SH, Chen CH, Lu HI, Huang WT, Tien WY, Lan YC, Lee CC, Chen YH, Huang HY, Chang AY, Lin WC.

Surgery. 2015 Mar;157(3):570-80. doi: 10.1016/j.surg.2014.10.014. Epub 2014 Nov 6.

PMID:
25726316
9.

Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence.

Cheung WL, Albadine R, Chan T, Sharma R, Netto GJ.

J Urol. 2009 Mar;181(3):1387-92. doi: 10.1016/j.juro.2008.10.146. Epub 2009 Jan 20.

PMID:
19157440
10.

Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.

Nishikawa M, Miyake H, Behnsawy HM, Fujisawa M.

Urol Oncol. 2015 Apr;33(4):166.e9-15. doi: 10.1016/j.urolonc.2014.12.006. Epub 2015 Jan 21.

PMID:
25618298
11.

[Sensitivity of esophageal squamous cell carcinoma cells to rapamycin can be improved by siRNA-interfered expression of p70S6K].

Liu M, Lu Z, Zheng Y, Cui Y, Wang J, Hou G.

Zhonghua Zhong Liu Za Zhi. 2015 Dec;37(12):885-9. Chinese.

PMID:
26887615
12.

Survivin and MKI67 mRNA expression in bladder washings of patients with superficial urothelial cell carcinoma correlate with tumor stage and grade but do not predict tumor recurrence.

Schultz IJ, Kiemeney LA, Willems JL, Swinkels DW, Witjes JA, de Kok JB.

Clin Chem. 2006 Jul;52(7):1440-2. No abstract available.

13.

Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.

Mhawech-Fauceglia P, Alvarez V, Fischer G, Beck A, Herrmann FR.

Am J Clin Pathol. 2008 Jun;129(6):918-23. doi: 10.1309/D81QMXPMC3QHT57Y.

PMID:
18480009
14.

Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder.

Han Y, Liu Y, Gui Y, Cai Z.

J Surg Oncol. 2013 Feb;107(2):201-5. doi: 10.1002/jso.23214. Epub 2012 Jul 5.

PMID:
22766726
16.

Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.

Patschan O, Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Lotan Y, Hotakainen K, Stenman UH, Bjartell A.

World J Urol. 2012 Dec;30(6):785-94. doi: 10.1007/s00345-011-0727-7. Epub 2011 Jul 8.

PMID:
21739120
18.

DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.

Conconi D, Panzeri E, Redaelli S, Bovo G, Volante M, Viganò P, Strada G, Dalprà L, Bentivegna A.

BMC Res Notes. 2012 Oct 31;5:607. doi: 10.1186/1756-0500-5-607.

19.

High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.

Li W, Liu M, Feng Y, Huang YF, Xu YF, Che JP, Wang GC, Zheng JH.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2430-40. eCollection 2013.

20.

High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.

Zhang Z, Zhang G, Kong C.

Urol Oncol. 2013 Oct;31(7):1222-30. doi: 10.1016/j.urolonc.2011.11.028. Epub 2011 Dec 20.

PMID:
22192978

Supplemental Content

Support Center